ESR1 and breast cancer: Molecular BC subtype [55] if luminal-like (ER+ and/or PR+), HER-2 overexpression (ER-, PR-, HER-2+), and triple-negative BC (TNBC) (ER-, PR-, HER-2-) and histological BC subtypes [56], whether invasive ductal carcinoma (IDC) or not, were all recorded for correlation analysis.